Last reviewed · How we verify
F2695
F2695 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cancer cells.
F2695 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cancer cells. Used for Advanced or metastatic solid tumors with FGFR alterations.
At a glance
| Generic name | F2695 |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
F2695 targets FGFR pathways that are frequently dysregulated in various solid tumors, leading to uncontrolled cell proliferation. By inhibiting FGFR kinase activity, the drug suppresses tumor cell growth and survival in FGFR-dependent malignancies. This mechanism is particularly relevant in cancers with FGFR gene amplifications, fusions, or mutations.
Approved indications
- Advanced or metastatic solid tumors with FGFR alterations
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
- Stomatitis
Key clinical trials
- Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder (PHASE3)
- Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging (PHASE1)
- Effect of F2695 on Functional Recovery After Ischemic Stroke (PHASE3)
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder (PHASE2)
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder (PHASE3)
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder (PHASE3)
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder (PHASE3)
- Safety Study of F2695 SR in Major Depressive Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F2695 CI brief — competitive landscape report
- F2695 updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI